Phaseline

Companies › Tenaya Therapeutics

Tenaya Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TN-201
Recombinant AAV9 delivering MYBPC3 transgene
MYBPC3Phase 1Hypertrophic CardiomyopathyAug 2027
TN-401
AAV9 gene therapy delivering PKP2 transgene
PKP2Phase 1Arrhythmogenic Right Ventricular CardiomyopathyOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05836259TN-201Phase 1Hypertrophic CardiomyopathyCardiovascularAug 2027
NCT06228924TN-401Phase 1Arrhythmogenic Right Ventricular CardiomyopathyCardiovascularOct 2029

From the company's SEC filings

Cash and short-term investments of $67m on 2026-09-30; operating cash outflow about $54m a year; runway about 15 months at that burn, to Dec 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PKP2 (1) MYBPC3 (1)

Companies with the same targets

Rocket Pharmaceuticals Lexeo Therapeutics Edgewise Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.